US Patent Granted for Preclinical Candidate PAT-LM1
Filed with ASX · · 1 page · English
Story so far
Earlier from Patrys
- PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
- PAT-DX1 Active in Pre-clinical Cancer Models
- Appendix 4E and 2017 Annual Report
- Appendix 4C - Quarterly - 30 June 2017
- Patrys Deoxymab 3E10 patent granted in the U.S.
Later from Patrys
- PAB and Garvan Institute of Medical Research Awarded Grant
- Appendix 4C - Quarterly - 30 September 2017
- Collaboration with WEHI
- PAT-DX1 is synergistic with PARP inhibitor
- Entitlement Offer Booklet
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys